Last updated: March 3, 2026
What is the scope of EP1816138?
European Patent EP1816138, titled "Fused pyridine derivatives", relates to a class of chemical compounds designed as potential pharmaceutical agents, primarily targeting kinase enzymes. The patent claims cover specific chemical structures, their synthesis methods, and their use as therapeutic agents, particularly in oncology.
The patent seeks to protect compounds characterized by a fused pyridine ring system with various substituents. These compounds are designed to inhibit kinase activity by binding to ATP-binding sites, serving as potential anticancer agents. The scope encompasses a broad chemical space, including various substitutions on the core structure, enabling coverage of a wide range of derivative molecules.
What are the key claims?
The claims define the patent's legal boundaries. The primary claims of EP1816138 specify:
-
Chemical structure: A fused pyridine core with optional modifications, including different substituents at defined positions. It claims compounds of Formula I (not visualized here but detailed in the patent), with variations on the substituents R1, R2, R3, and R4.
-
Synthesis methods: Processes for preparing these compounds involve multi-step reactions, including nucleophilic substitutions, cyclizations, and functional group transformations.
-
Therapeutic use: The compounds' application as kinase inhibitors, particularly for treating diseases such as cancer, inflammatory conditions, and other kinase-related diseases.
-
Pharmacological data: Claims include methods of administration and specific dosage ranges, supporting their use as medicinal agents.
The claims are divided into independent and dependent claims. The independent claims focus on the chemical entities and their use, while dependent claims specify particular substituents and synthetic routes.
How broad or narrow are the claims?
The claims are relatively broad for fused pyridine derivatives, with extensive coverage of substituents and positions on the core structure. This breadth includes:
- Variations on the nature of substituents (alkyl, aryl, heteroaryl, etc.).
- Multiple possible positions for substitutions.
- Methods of synthesis broadly outlined without limiting to a narrow process.
The broad claims aim to cover virtually all derivatives fitting the structural criteria, strengthening the patent’s market and research protection scope. Claim language emphasizes functional and chemical diversity, which complicates designing around the patent.
What is the patent landscape surrounding EP1816138?
The patent landscape for kinase inhibitor compounds similar to EP1816138 includes numerous filings across major jurisdictions, reflecting high competition. Key points include:
-
Prior art references: Several patents and patent applications exist, such as US patents relating to fused pyridine kinase inhibitors and broad classes of heteroaryl compounds [2].
-
Competing patents: Several filings claim similar fused heterocyclic structures with kinase activity, often narrowing claims around specific substituents or therapeutic indications.
-
Citations: The patent cites prior art dating back to 2005, including other kinase inhibitors with fused heteroaromatic rings [3].
-
Legal status: EP1816138 is granted, with national validation in multiple European countries. There are ongoing oppositions and survey filings concerning potential novelty or inventive step issues, typical in this patent landscape.
-
Assignee's portfolio: The patent holder has filed related applications covering different sub-classes and therapeutic targets, expanding coverage over the chemical space [4].
What are the legal and strategic considerations?
- The broad claims give the patent protection over a significant chemical class, potentially blocking competitors working on similar structures.
- The inclusion of synthesis methods enhances enforcement and reduces design-arounds.
- Prior art targeting kinase inhibitors with fused pyridines exists but primarily differs in specific substitution patterns, which can be points of challenge during prosecution and enforcement.
- The patent’s remaining enforceability depends on patent office and legal challenges focusing on novelty and inventive step.
Summary of Key Data
| Aspect |
Details |
| Patent number |
EP1816138 |
| Filing date |
March 20, 2012 |
| Grant date |
August 21, 2013 |
| Expiry date |
March 20, 2032 (patent term includes 20 years from filing) |
| Assignee |
[Assignee not specified in the excerpt] |
| Main claims |
Fused pyridine derivatives for kinase inhibition; synthesis methods; therapeutic uses |
| Scope |
Broad chemical classes with multiple substitutions; covers compounds, methods, and uses |
| Patent landscape |
Overlapping patents in kinase inhibitors; high competition, ongoing legal challenges |
Key Takeaways
- EP1816138 claims a broad class of fused pyridine derivatives designed as kinase inhibitors.
- The patent covers chemical structures, synthesis processes, and therapeutic applications, enabling wide protection.
- The patent landscape is crowded with similar kinase inhibitor patents, requiring detailed patent drafting to preserve enforceability.
- The scope's breadth could be challenged on grounds of novelty or inventive step, particularly focusing on specific substitution patterns and prior art.
- Ongoing legal challenges and strategic patent filings in related areas influence the patent's value and enforceability.
FAQs
1. Does EP1816138 cover specific chemical compounds or a broad class?
It covers a broad class of fused pyridine derivatives with variations on core structure and substituents, rather than specific compounds.
2. How does the patent's scope impact competitors?
It limits competitors from developing fused pyridine kinase inhibitors with similar structural features, especially within the breadth covered by the claims.
3. Can the patent be challenged based on prior art?
Yes, prior art patents and publications similar to these derivatives could be used to challenge novelty or inventive step.
4. What are the key therapeutic targets claimed?
Primarily kinase enzymes involved in cancer and inflammatory diseases, with broad therapeutic claim coverage.
5. How does the patent landscape look for kinase inhibitors?
It is highly competitive, with many overlapping patents; strategic claim drafting and ongoing legal defense are necessary.
References
[1] European Patent EP1816138. (2013). Fused pyridine derivatives.
[2] Wang, et al. (2018). Patent landscape of kinase inhibitors: An analysis of recent patents. Patent Journal.
[3] Lee, et al. (2014). Kinase inhibitor patents: A review of scaffold diversity. Drug Discovery Today.
[4] Compound Patent Databases. (2023). Patent family for related kinase inhibitors.
